Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP808772.RAfrf_L4upawssZiGUtyNQfYd48UFZHhxEIZ2He9e0vKc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP808772.RAfrf_L4upawssZiGUtyNQfYd48UFZHhxEIZ2He9e0vKc130_assertion type Assertion NP808772.RAfrf_L4upawssZiGUtyNQfYd48UFZHhxEIZ2He9e0vKc130_head.
- NP808772.RAfrf_L4upawssZiGUtyNQfYd48UFZHhxEIZ2He9e0vKc130_assertion description "[CMD biochemical types include various abnormalities of alpha-dystroglycan O-mannosyl glycosylation as well as defects in integrin matrix receptors, the extracellular matrix proteins laminin-alpha(2) and collagen VI, nuclear proteins such as lamin A/C, and a protein of the endoplasmic reticulum, selenoprotein N. Current therapies are directed mostly at supportive care; however, recent advances in biotechnology and increased knowledge of the pathophysiology underlying the various CMD types have helped identify potential therapeutic strategies directed at genetic, molecular, and biochemical pathways involved in these disorders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP808772.RAfrf_L4upawssZiGUtyNQfYd48UFZHhxEIZ2He9e0vKc130_provenance.
- NP808772.RAfrf_L4upawssZiGUtyNQfYd48UFZHhxEIZ2He9e0vKc130_assertion evidence source_evidence_literature NP808772.RAfrf_L4upawssZiGUtyNQfYd48UFZHhxEIZ2He9e0vKc130_provenance.
- NP808772.RAfrf_L4upawssZiGUtyNQfYd48UFZHhxEIZ2He9e0vKc130_assertion SIO_000772 20425232 NP808772.RAfrf_L4upawssZiGUtyNQfYd48UFZHhxEIZ2He9e0vKc130_provenance.
- NP808772.RAfrf_L4upawssZiGUtyNQfYd48UFZHhxEIZ2He9e0vKc130_assertion wasDerivedFrom befree-2016 NP808772.RAfrf_L4upawssZiGUtyNQfYd48UFZHhxEIZ2He9e0vKc130_provenance.
- NP808772.RAfrf_L4upawssZiGUtyNQfYd48UFZHhxEIZ2He9e0vKc130_assertion wasGeneratedBy ECO_0000203 NP808772.RAfrf_L4upawssZiGUtyNQfYd48UFZHhxEIZ2He9e0vKc130_provenance.